Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
NOVARTIS AG
Bear Case (25th pct.)
-35.3% vs price
Base Case (Median)
-0.7% vs price
Bull Case (75th pct.)
25.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $242.23 | 48.1% | High (40%) |
| PE Comparable | $162.52 | -0.7% | Medium (25%) |
| Growth Trajectory DCF | $239.04 | 46.1% | Medium (20%) |
| Graham Number | $61.87 | -62.2% | Medium (40%) |
| EV/EBITDA | $84.55 | -48.3% | Medium (20%) |
| EV/FCF | $170.83 | 4.4% | Medium (20%) |
| Earnings Power Value | $127.27 | -22.2% | Medium (50%) |
Based on 7 out of 7 methods, NVSEF appears fairly valued at the current price of $163.60. The base case fair value of $162.52 implies 0.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.